NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Fennec Pharmaceuticals Inc. Common Stock (FENC) Stock Analysis

Fennec Pharmaceuticals Inc. Common Stock (FENC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

FENC

$12.39

−$0.16 (−1.27%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FENC with… →

FENC Key Statistics

As of Sep 4, 2026
Trading
Open
$12.45
Previous Close
$12.55
Day's Range
12.29–12.60
52-Week Range
5.65–13.25
Volume
212.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.10
Valuation
Market Cap
$434.48M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
13.01
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.47
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.34
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.12
Financials (FY)
Revenue (FY)
$44.64M−6.09%
Net Income (FY)
−$9.74M
Profit marginThe share of revenue left as profit after all costs and taxes.
−5.49%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
35.07M
1-Year Return
+34.97%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
231.85K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

FENC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+60.91%
2025+21.84%
2024−43.67%
2023+16.88%
2022+118.18%
2021−40.94%
2020+14.79%
2019+1.72%
2018−36.33%
2017 (partial year)−16.50%

As of September 4, 2026.

FENC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$44.64M−$9.74M−21.8%
2024$47.54M−$436.00K−0.9%
2023$21.25M−$16.05M−75.5%
2022$1.54M−$23.71M−1544.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$44.64M$40.88M−$6.35M−$9.74M−21.8%
2024$47.54M$44.35M$2.48M−$436.00K−0.9%
2023$21.25M$19.99M−$13.06M−$16.05M−75.5%
2022$1.54M$1.45M−$22.74M−$23.71M−1544.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FENC Valuation vs Biotechnology Median

Median of 656 stocks
MetricFENCBiotechnology medianvs median
P/S ratio7.3415.2652% below
Profit margin−5.49%0.00%5.5 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Fennec Pharmaceuticals Inc. Common Stock (FENC) is capitalised at $434.48M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 35 employees.

The most recent close on file for FENC is $12.39, dated September 4, 2026. That is −$0.16 (−1.27%) against the previous close. Over the past 52 weeks the price has ranged from $5.65 to $13.25. The latest close sits 119.29% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $44.64M. That is −6.09% against the prior fiscal year, when revenue was $47.54M. The same year closed with a net loss of $9.74M. Profit margin runs at −5.49%. That is 5.5 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.12.

Across the 4 fiscal years on file, revenue moves from $1.54M in 2022 to $44.64M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 13.01. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.47. The price-to-sales ratio is 7.34. On price-to-sales that is 51.93% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +34.97%. Measured over 5 years, that is +9.31% a year compounded. Beta against the wider market is reported at 1.1. Annualized volatility over the trailing 9 years is 59.88%.

Growth & Income

The record shows no dividend for FENC.

So far in 2026 the price is +60.91%. Across the complete calendar years on file, 2022 returned +118.18% and 2024 returned −43.67%. Of the 8 complete calendar years on file, 5 finished higher.

Peer Comparison

Fennec Pharmaceuticals Inc. Common Stock (FENC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Fennec Pharmaceuticals Inc. Common Stock FENC $434.48M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Fennec Pharmaceuticals Inc. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Fennec Pharmaceuticals Inc. Common Stock

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Visit website →